Lupin Joins Forces with Zentiva to Develop TNF-Alpha Inhibitor Biosimilar

Shots:Zentiva has entered into a license & supply agreement with Lupin to commercialize Lupin's TNF-alpha inhibitor biosimilar across multiple global marketsZentiva will lead commercialization outside the US & Canada, mainly in EU & CIS, while Lupin will handle development, manufacturing, & supply in agreed territories & commercialization in the remaining territories, incl. the…

ByRidhi RastogiJuly 9, 2025

News

Lupin Collaborates with SteinCares to Commercialize Ranibizumab Biosimilar in Latin America

Shots:Lupin & SteinCares have entered into a license & supply agreement to commercialize Lupin’s ranibizumab biosimilar in Latin America excl. Mexico & ArgentinaAs per the deal, SteinCares will be responsible for the biosimilar’s regulatory filings, registration, & commercialization in LATAM licensed states, while Lupin will oversee its manufacturingRanibizumab is a recombinant humanized…

ByRidhi RastogiMay 26, 2025

News

Lupin Reports the P-III Study Completion of LUBT010 (Biosimilar, Lucentis) for Neovascular Age-related Macular Degeneration

Shots: Lupin has concluded P-III study evaluating the efficacy, safety & immunogenicity of LUBT010 (0.5mg, intravitreal, QM for 1yr.) vs Lucentis in wet AMD adults (n=600) across India, US, EU & Russia The trial met its 1EP, showing therapeutic equivalence in visual acuity improvement plus similarity in safety & immunogenicity b/w both the drugs. Results will…

ByDipanshu DixitAugust 5, 2024

News

Lupin and Sandoz Launch Rymti (Biosimilar, Enbrel) in Canada to Treat Plaque Psoriasis

Shots: Followed by HC’s approval in Aug 2022, Lupin with its partner Sandoz launched Rymti (biosimilar, Enbrel) in Canada The study showed that Rymti has equivalent safety and efficacy to Enbrel. It is a solution for injection in the form of a pre-filled pen & pre-filled syringe Rymti is intended to treat children and…

ByDipanshu DixitMay 3, 2024

INSIGHTS+

Insights+ Key Biosimilars Events of May 2023

Shots:Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patientsDuring the month of May, Celltrion’s Yuflyma (biosimilar, adalimumab) received the…

BySenior EditorJune 7, 2023

TOP 20

Top 20 Generics Pharma Companies Based on 2021 Total Revenue

Shots:With an increased price range and the lack of accessibility of branded products, the generic version of these products has been established to be more affordable and accessible to patients, providers, and the healthcare system. Therefore, Generic medicines are a bioequivalent substitute for a marketed brand-name drug, developed after the expiry of the patent…

ByPrince GiriOctober 13, 2022

INSIGHTS+

Insights+ Key Biosimilars Events of September 2022

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patientsDuring the month of September, Fresenius Kabi’s Stimufend (biosimilar, pegfilgrastim) received the…

BySenior EditorOctober 6, 2022

INSIGHTS+

Insights+ Key Biosimilars Events of August 2022

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patientsDuring the month of August, Formycon reported P-III (VESPUCCI) trial results of…

BySenior EditorSeptember 1, 2022

INSIGHTS+

Insights+ Key Biosimilars Events of December 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patientsDuring the month of December, Samsung Bioepis presented five-year follow-up results of…

BySenior EditorJanuary 6, 2022

TOP 20

Top 20 Generics Pharma Companies Based On 2020 Revenue

Shots:Generic medicines are the backbone of the healthcare system and are identical to the innovator medicine in strength- effect- dosage form- and route of administration. These are allowed for sale after the patent expiry of the original drugsOur team at PharmaShots has compiled a list of the top 20 generic companies based on…

ByPrince GiriOctober 28, 2021

Lupin Joins Forces with Zentiva to Develop TNF-Alpha Inhibitor Biosimilar

Lupin Collaborates with SteinCares to Commercialize Ranibizumab Biosimilar in Latin America

Lupin and Sandoz Launch Rymti (Biosimilar, Enbrel) in Canada to Treat Plaque Psoriasis

Insights+ Key Biosimilars Events of May 2023

Top 20 Generics Pharma Companies Based on 2021 Total Revenue

Insights+ Key Biosimilars Events of September 2022

Insights+ Key Biosimilars Events of August 2022

Insights+ Key Biosimilars Events of December 2021

Top 20 Generics Pharma Companies Based On 2020 Revenue

Contact US

OUR INFORMATION

FOLLOW US